ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

16,899Medicare Part D Prescriptions Filled, Including Refills

Rank: 259 out of 6645

$1.51M Total Retail Price of All Prescriptions

Rank: 136 out of 6645

891 Patients Receiving at Least One Drug in Part D
92%Patients 65 Years and Older
90% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

21% of this provider’s 891 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

3% of this provider’s 15,969 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$90 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
SIMVASTATIN 1,407 1,337 1 1
AMLODIPINE BESYLATE 1,121 1,085 2 2
LOSARTAN POTASSIUM 862 841 3 12
METOPROLOL SUCCINATE 685 666 4 24
DIOVAN 561 529 5 19
OMEPRAZOLE 491 465 6 6
PRAVASTATIN SODIUM 478 465 7 20
PANTOPRAZOLE SODIUM 395 384 8 29
TAMSULOSIN HCL 373 372 9 22
AMOX TR-POTASSIUM CLAVULANATE 369 342 10 10 185
METFORMIN HCL 355 321 11 7
ACETAMINOPHEN-CODEINE 337 327 S3 12 80
FLUTICASONE PROPIONATE 315 295 13 26
JANUVIA 288 279 14 38
TRIAMCINOLONE ACETONIDE 280 263 15 55
FUROSEMIDE 277 263 16 11
ALLOPURINOL 272 260 17 31
ADVAIR DISKUS 244 235 18 45
COMBIVENT 237 223 19 174
GLIPIZIDE 224 188 20 23
ATENOLOL 213 209 21 8
KETOCONAZOLE 210 181 22 196
PROMETHAZINE HCL 209 170 R 23 219
LEVOTHYROXINE SODIUM 205 196 24 4
PROAIR HFA 183 161 25 32
PREDNISONE 178 165 26 57
COLCRYS 169 165 27 192
ALENDRONATE SODIUM 160 156 28 14
RAMIPRIL 159 151 29 118
NAMENDA 154 154 30 41
MECLIZINE HCL 154 150 30 122
SINGULAIR 152 147 32 76
ZOLPIDEM TARTRATE 145 140 33 17
CLOPIDOGREL 144 129 34 36
ATORVASTATIN CALCIUM 141 136 35 10
DONEPEZIL HCL 135 135 36 27
CARVEDILOL 126 125 37 25
FAMOTIDINE 121 106 38 33
WARFARIN SODIUM 117 103 39 16
BENAZEPRIL HCL 116 108 40 21
PLAVIX 112 101 41 49
HYDROCORTISONE 112 100 41 229
LISINOPRIL 111 106 43 3
ACTOS 110 106 44 71
SYMBICORT 110 106 44 153
GLYBURIDE-METFORMIN HCL 110 105 R 44 95
LOVASTATIN 104 100 47 15
ISOSORBIDE DINITRATE 102 97 48 200
CIPROFLOXACIN HCL 93 88 49 67
FINASTERIDE 91 91 50 73
MONTELUKAST SODIUM 91 86 50 128
HYDROCHLOROTHIAZIDE 89 72 52 9
HYDROXYZINE HCL 88 69 R 53 161
NEXIUM 78 75 54 40
GABAPENTIN 78 71 54 18
VENTOLIN HFA 76 73 56 146
HYDRALAZINE HCL 73 70 57 77
MEGESTROL ACETATE 72 65 R 58 104
BENICAR 70 68 59 84
DEXILANT 66 50 60 102
HYDROCODONE-ACETAMINOPHEN 62 43 S3 61 5
LEVOFLOXACIN 61 60 62 83
SPIRIVA 59 59 63 65
LOSARTAN-HYDROCHLOROTHIAZIDE 59 59 63 62
DIOVAN HCT 58 56 65 64
AZITHROMYCIN 54 51 66 44
ASPIRIN EC 51 51 67 264
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 6, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.